Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Astellas Pharma Global Development, Inc (APGD)
Femme et Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects
The objective of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
The objective of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects who are Methotrexate-Inadequate Responders (MTX-IR).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer
To determine the PFS of MDV3100 as compared to bicalutamide
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
To determine objective response rate (ORR) (complete remission [CR] + partial remission [PR]) per [the International Working Group (IWG) Revised Response Criteria for Malignant Lymphomas (2007)].
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis
To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
A Multinational study, Phase 3, Randomized, Double-blind, and controlled against a Placebo that studies the Efficacy and the Safety of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by radiographic progression-free survival (rPFS) based on central review
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Determine the efficacy superiority of ASP2215 and/or ASP2215 plus azacitidine versus azacitidine as measured by overall survival (OS).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
Effectiveness and safety of gilteritinib (ASP2215) as maintenance treatment (maintain the response achieved during the first course of treatment) for Acute myeloid leukemia patients who are in a first complete remission (no residual leukemia cells in your bone marrow), with mutations in the FLT3 gene compared to placebo given alone. Fenntartó kezelésként alkalmazott gilteritinib (ASP2215) hatásosságának és biztonságosságának vizsgálata első teljes remisszió időszakában levő (tumorsejt nem található a csontvelőben), FLT3 génmutációval rendelkező, akut myeloid leukémiában szenvedő betegek körében, placebóhoz viszonyítva
The primary objective is to compare relapse-free survival (RFS) between subjects with FLT3/ITD AML in first complete remission (CR1) without transplant and who are randomized to receive gilteritinib o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects with Stage III (Unresectable) or Stage IV Melanoma
To evaluate 6-month Progression Free Survival (PFS).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Global Development, Inc (APGD)
MAJ Il y a 4 ans
A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic Atrial Fibrillation
The primary safety objective of this study is to evaluate the safety of vernakalant injection in subjects with recent onset (AF > 3 hours to less than or equal to 7 days), symptomatic atrial fibrillat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
1
2
Suivant